Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622208 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL2622209 | 1.00 | CHRM2 (0.59) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL22845470 | 0.82 | OPRK1 (0.47) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL6544199 | 0.82 | CHRM2 (0.55) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL6226291 | 0.80 | CHRM2 (0.44) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL10315775 | 0.79 | SMN1; SMN2 (0.39) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL11059931 | 0.79 | MEN1 (0.45) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL8254526 | 0.79 | SMN1; SMN2 (0.39) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL8259486 | 0.79 | SMN1; SMN2 (0.39) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 | |
| SCHEMBL14469645 | 0.79 | OPRK1 (0.47) | CHRM2CHRM1ADRA1ASLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747366-A1 | PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025017089-A1 | PROCESS FOR THE REDUCTION OF AROMATIC IMINES WITH NOVEL IMINE REDUCTASES (IREDS) | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| US-20240207353-A1 | USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11220486-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) | 2022-01-11 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210230155-A1 | PROCESS FOR PREPARATION OF ((3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DI(METHOXY-D3)-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-ONE | HETERO LABS LIMITED (IN) | 2021-07-29 | — | — | US | disclosed |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2020-09-17 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070269405-A1 | Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-11-22 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-4727149-A | Preparation of nitriles of fused ring pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1988-02-23 | — | — | US | disclosed |
| US-4707552-A | Preparation of nitriles and thioamides of fused ring pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1987-11-17 | — | — | US | disclosed |
| US-4529798-A | Reacting the correcponding lithium, sodium, potassium or magnesium halide compound with a aminonitrile compound | JOHN WYETH & BROTHER LIMITED (GB) | 1985-07-16 | — | — | US | disclosed |
| EP-0054384-B1 | PROCESS FOR PREPARING PYRIDINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1984-06-27 | — | — | EP | disclosed |
| EP-0054384-A1 | Process for preparing pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220486-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof | ACP1, PTPRCAP, PTPA | CHRM2 4872/4885CHRM1 4861/4885ADRA1A 4463/4885 |
| US-20070269405-A1 | Androgen Receptor Modulators | AR, SHBG, FSHR | CHRM2 803/4885CHRM1 1044/4885ADRA1A 101/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885CHRM1 4819/4885ADRA1A 4489/4885 |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | ACP1, PTPRCAP, PTPA | CHRM2 4872/4885CHRM1 4861/4885ADRA1A 4463/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CHRM2 495/4885CHRM1 463/4885ADRA1A 194/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | CHRM2 1578/4885CHRM1 1909/4885ADRA1A 3712/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | CHRM2 4812/4885CHRM1 4819/4885ADRA1A 4489/4885 |
| US-20240207353-A1 | USE OF PEPTIDE AMIDE COMPOUND IN PREPARATION OF DRUG FOR TREATING PRURITUS | VIP, GRPR, ITCH | CHRM2 1610/4885CHRM1 2147/4885ADRA1A 1318/4885 |
| US-20210230155-A1 | PROCESS FOR PREPARATION OF ((3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DI(METHOXY-D3)-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-ONE | CYP4B1, CYP1B1, UGT1A3 | CHRM2 359/4885CHRM1 164/4885ADRA1A 147/4885 |
| US-11014964-B2 | Peptide amide compound and preparation method and medical use thereof | VIP, NPPA, GRPR | CHRM2 3646/4885CHRM1 3942/4885ADRA1A 2127/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | CHRM2 523/4885CHRM1 541/4885ADRA1A 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.